CA-CEPTON-TECHNOLOGIES
11.11.2021 15:02:12 CET | Business Wire | Press release
Cepton Technologies, Inc. announced today that it has been named a CES® 2022 Innovation Awards Honoree in the Vehicle Intelligence & Transportation category for its Nova lidar , a miniature, wide field of view lidar sensor for near-range applications. The announcement was made ahead of CES 2022 , a global consumer electronics and consumer technology trade show that will be held from January 5-8 in Las Vegas, NV and digitally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005540/en/
The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)® , is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. An elite panel of industry expert judges , including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design. The Nova lidar has been selected among a record high number of submissions to this year’s program, signifying the weight of Nova’s technology and design value for the automotive market.
Nova features a miniature form factor and a wide field of view, making it ideally suited for seamless integration into modern vehicles. With a target volume price point under $100, Nova sets a worldwide benchmark with its unprecedented combination of compactness, field of view coverage and targeted affordability.
Nova is designed to help minimize perception blind spots to enhance advanced driver assistant systems (ADAS) and autonomous driving (AD) capabilities.
It aims to address major gaps in proximity detection of objects with current sensor technologies such as cameras, radars and ultrasonic sensors. Powered by Cepton’s patented Micro Motion Technology (MMT® ) , Nova enables high-resolution 3D imaging to accurately detect small children, on-road objects, protrusions and road edges etc. to help increase vehicle safety and enable a higher level of autonomy. Compared to some other near-range lidars , Nova achieves a higher field of view in both horizontal (120°) and vertical (60°) directions with significantly lower size, power and weight.
Benefiting from the maturity of MMT and Cepton’s proprietary lidar engine ASIC for advanced signal processing, Nova is built to meet the stringent requirements of the automotive industry. An automotive-grade lidar , it supports ASIL-B functional safety and consumes <3.5 W (typical power). Nova can be elegantly embedded all around an automobile to provide a complete 360° view of a vehicle’s immediate surroundings, without disrupting the vehicle’s design aesthetics.
In addition to automotive applications, Nova can also enable autonomous robotics and ground vehicles for industrial applications.
Earlier this year, Nova was a second-place award winner at the 2021 Tech.AD Europe Awards , in the category of Most Innovative Use of Artificial Intelligence & Machine Learning in the Development of Autonomous Vehicles & Respective Technologies.
“The key value proposition of the Nova lidar is its combination of a wide horizontal and vertical field of view, the very compact size, the low power consumption and an attractive volume price,” said Dr. Jun Pei, CEO of Cepton.
“With that, we hope to significantly enhance vehicle safety in everyday passenger cars by making Nova a mass-market lidar solution . In addition, it uses a scaled version of Cepton’s patented MMT architecture that is already in use in the long-range lidars that we are supplying in our major ADAS lidar program with our key OEM customer . We believe that this means that the core technology enabling Nova has reached a high maturity level and is licensable to manufacturing partners, especially automotive Tier 1s .”
Detailed information about the CES 2022 Innovation Awards honorees can be found at CES.tech/innovation . In January 2022, Cepton will join many other honorees in showcasing their products in the Innovation Awards Showcase area at CES 2022. At the Cepton Booth (#5518, LVCC – West Hall), Cepton will also showcase Nova alongside its comprehensive portfolio of lidar solutions for smart mobility , covering automotive and smart infrastructure applications . Please visit the Cepton website for more information.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press release
Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous
Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press release
Megaport’s expansion to Portugal unlocks access to compute, network, and storage services for the local and global markets. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom